The Trump administration is reportedly ready to move ahead with marijuana rescheduling.
More than four months after President Donald Trump signed an executive order directing the attorney general to expeditiously finish the process of moving cannabis from Schedule I to Schedule III of the Controlled Substances Act (CSA), the administration may be finally prepared to move forward.
Citing an administration official familiar with the matter, Axios reported that action could come as soon as Wednesday.
The Washington Post added that the Drug Enforcement Administration (DEA) is planning to announce a new administrative hearing on cannabis rescheduling, citing two sources.
Early last year, a DEA administrative law judge canceled a prior hearing process on marijuana rescheduling amid litigation from pro-reform parties that alleged improper agency communications and witness selection decisions.
The Post’s sources cautioned that the administration’s current rescheduling plans could change ahead of an official announcement.
A White House official told Marijuana Moment on Wednesday that “the administration continues to expeditiously implement President Trump’s December executive order to increase medical marijuana research to close the gap between current medical marijuana use and medical knowledge.”
The official referred questions about “specifics related to possible reclassification” to the Department of Justice, but a spokesperson there was not immediately available.
Rescheduling wouldn’t federally legalize cannabis, but it would remove certain Schedule I research barriers, while benefitting state-licensed marijuana businesses by allowing them to take federal tax deductions they’re currently barred from under an Internal Revenue Service (IRS) code known as 280E.
There has been some uncertainty about how the Department of Justice (DOJ) will navigate the issue. While the department faced a mandate from the president, top officials have been notably silent on the issue in the months since receiving that directive—even as the White House touted Trump’s order as an example of a policy achievement during the first year of his second term.
Trump himself complained last weekend that federal officials were “slow-walking” following through on his cannabis order.
“You’re going to get the rescheduling done, right, please? Will you get the rescheduling done, please?” Trump said during a signing ceremony for a separate order on psychedelics, seeming to speak to a Department of Justice or White House official during an event in the Oval Office on Saturday. “You know, they’re slow-walking me on rescheduling. You’re going to get it done, right?”
A Justice Department spokesperson told Marijuana Moment in January that they had no “comment or updates” to share on the topic. However, an agency official more recently said that DOJ was “working to identify the most expeditious means of executing the EO.”
That phrasing was notable, signaling that the department was uncertain about the administrative pathway to finalize rescheduling. The hope among advocates and industry stakeholders was that the process would be more simple, with a final signature on the existing reform proposal that was released following a scientific review initiated under the prior Biden administration.
When Trump issued the rescheduling order late last year, Pam Bondi was attorney general. She opposed cannabis reform as Florida’s attorney general and she didn’t attend the president’s signing ceremony for the rescheduling executive order.
Now, the process is being overseen by Acting Attorney General Todd Blanche, who said in response to a written question about marijuana rescheduling during his confirmation process to become deputy attorney general that he would “give the matter careful consideration after conferring with all relevant stakeholders, including DEA personnel.”
DEA and reform proponents earlier this month submitted a joint status report on an interlocutory appeal that concerns allegations of agency bias and improper communications with anti-rescheduling parties during the review process on the proposal.
“To date, Movants’ interlocutory appeal to the Administrator regarding their Motion to Reconsider remains pending with the Administrator,” the filing from attorneys representing DEA and cannabis reform proponents challenging the process says. “No briefing schedule has been set.”
The president’s rescheduling directive was overwhelmingly popular among cannabis consumers, according to a recent poll from the cannabis telehealth platform NuggMD.
About 83 percent of respondents said they support the executive order, compared to 7 percent who expressed opposition and 10 percent who said they didn’t have an opinion about the proposed reform.
Former Rep. Matt Gaetz (R-FL), Trump’s first pick for attorney general this term who ultimately withdrew his nomination, recently raised eyebrows after posting on X that he’s been told that DEA is actively drafting a rescheduling rule and intended to issue it “ASAP.”
There was some confusion around that point, however, as a rule was already pending before the Justice Department—and a new rule would have presumably been subject to additional administrative review and public comment.
A Democratic senator told Marijuana Moment in January that it’s “too early to tell” what the implications of Trump’s cannabis order would be—saying that while there are “things that look promising” about it, he is “very concerned about where the DOJ will land.”
“The ability of the Trump administration to speak out of both sides of their mouth is staggering,” Sen. Cory Booker (D-NJ) said. “So I’m just going to wait and see right now. Obviously, there’s things that look promising—to end generations of injustice. I really want to wait and see.”
—
Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.
Learn more about our marijuana bill tracker and become a supporter on Patreon to get access.
—
Also in January, two GOP senators filed an amendment to block the Trump administration from rescheduling cannabis, but it was not considered on the floor.
A recent Congressional Research Service (CRS) report discussed how DOJ could, in theory, reject the president’s directive or delay the process by restarting the scientific review into marijuana.
The Department of Justice separately missed a congressionally mandated deadline in January to issue guidelines for easing barriers to research on Schedule I substances such as marijuana and psychedelics.
Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
